MGNX logo

MacroGenics, Inc.

MGNX
Healthcare|Biotechnology|US
$2.33
+0.11 (+4.95%)
Tangible Book / Share
$0.67
Cash / Share
$2.73
Next Earnings Report
Nov 11, 2026
EPS est. -$0.32 · Revenue est. $39.2M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (7)

May 2027
Est. completion
P2Colorectal Cancer
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
NCT07071961n=16
Jul 2027
Est. completion
P2Platinum-resistant Ovarian Cancer
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347n=80
Jun 2028
Est. completion
P2Metastatic Cancer
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
NCT05475171n=60
Sep 2028
Est. completion
P1Urothelial Cancer
A Study of MGC030 in Participants With Advanced Solid Tumors
NCT07822399n=314
Oct 2028
Est. completion
P1Advanced Solid Tumor
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470n=394
Mar 2029
Est. completion
P2Prostate Cancer
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255n=219
Jan 2032
Est. completion
P2Pancreatic Adenocarcinoma
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
NCT07565155n=40

Awaiting Results (4)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P1
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773
Mar 2025
P2
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
NCT06227546
Oct 2024
P2
MARGetuximab Or Trastuzumab (MARGOT)
NCT04425018
Aug 2020
P2
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
NCT02923180

Recent Press Releases

MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D.
Nov 3, 2026 · GlobeNewsWire
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
Oct 26, 2026 · GlobeNewsWire
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
Oct 23, 2026 · GlobeNewsWire
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
Oct 15, 2026 · GlobeNewsWire
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026 · GlobeNewsWire
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
Aug 13, 2026 · GlobeNewsWire
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
Aug 11, 2026 · GlobeNewsWire

SEC Filings (65)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 20268-KMaterial eventDocumentIndex
Oct 23, 20268-KMaterial eventDocumentIndex
Sep 3, 2026S-8Employee stock planDocumentIndex
Sep 3, 20268-K/AMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 3, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 23, 20268-KMaterial eventDocumentIndex
Jul 20, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 8, 20268-KMaterial eventDocumentIndex
Jul 7, 20268-KMaterial eventDocumentIndex
Jun 5, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 20, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 22, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 8, 20268-KMaterial eventDocumentIndex
Apr 8, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 8, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Mar 9, 202610-KAnnual reportDocumentIndex
Mar 2, 20268-KMaterial eventDocumentIndex
Feb 24, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 20, 20258-KMaterial eventDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025S-8Employee stock planDocumentIndex